Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,800
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
stocks
Bapcor is paying for the sins of its past
stocks
Overvalued ASX share as market underestimates downside risks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,390.10 | 16.40 | 0.17% |
CAC 40 | 8,225.73 | 19.66 | 0.24% |
DAX 40 | 24,264.29 | 5.49 | 0.02% |
Dow JONES (US) | 46,830.55 | 123.97 | 0.27% |
FTSE 100 | 9,407.22 | 3.65 | 0.04% |
HKSE | 26,027.55 | 168.72 | 0.65% |
NASDAQ | 22,939.73 | 50.81 | -0.22% |
Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
S&P 500 | 6,732.13 | 3.00 | -0.04% |
S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
SSE Composite Index | 3,916.33 | 52.44 | 1.36% |